Lumbales „ancient“ Schwannom – Fallbericht und Review einer seltenen Entität im dermatopathologischen Alltag

Zusammenfassung

Schwannome sind benigne periphere Nervenscheidentumoren, welche von den Hüllstrukturen der Nervenzellen, den Schwann-Zellen, ausgehen. Sie können sich peripher, viszeral, intraspinal und intrakranial manifestieren, wobei es sich überwiegend um langsam über Jahre wachsende, solitäre Tumoren handelt, welche sich meist im mittleren Alter manifestieren. Schwannome sind selbst schmerzlos, Symptome kommen erst durch Kompression benachbarter Strukturen zustande. Histologisch werden 5 Subtypen der Schwannome unterschieden, wobei hier eine Übersicht über diese Subklassen gegeben wird. Die im Folgenden geschilderte Patientenvorstellung präsentiert einen Fall eines schnell gewachsenen sog. „ancient“ Schwannoms bei einem 26-jährigen Patienten lumbal.

Abstract

Schwannomas are benign peripheral nerve sheath tumors, originating from sheath structures of nerve cells, the so called Schwann cells. They can grow as peripheral, visceral, intraspinal or intracranial tumours. Schwannomas primarily represent solitary tumors, slowly progressing over years and manifest mostly in the middle age. Schwannomas themselves are painless; symptoms only appear through compression of adjacent structures. Histologically, five subtypes of schwannomas can be distinguished. An overview of these subclasses is given with this case. This presentation displays a case of a rapidly growing “ancient schwannoma” at the lumbar region in a 26-year-old male patient.

• Literatur

• 1 Shah AA, Latoo S, Ahmad I et al. Schwannoma causing resorption of zygomatic arch. J Oral Maxillofac Pathol 2011; 15: 80-84
• 2 Colreavy MP, Lacy PD, Hughes J et al. Head and neck schwannomas – a 10 year review. J Laryngol Otol 2000; 114: 119-124
• 3 Verocay J. Zur Kenntnis der Neurofibrome. Beitr Pathol Anat 1910; 156: 1-68
• 4 Masson P. Experimental and Spontaneous Schwannomas (Peripheral Gliomas). Am J Pathol 1932; 8: 367-388
• 5 Schöfer H, Baur-Beger S. Derma-Net-Online 2014. Wiesbaden: BBS Verlags GmbH und Co. KG; 2014
• 6 Matsui F, Kobori Y, Takashima H et al. A case of intrascrotal schwannoma. Hinyokika Kiyo 2002; 48: 749-751
• 7 Weiss SW, Goldblum JR. Enzinger and Weiss’s Soft Tissue Tumors. 4th ed. Saint Louis, Missoury: Mosby; 2001
• 8 Zachariades N. Schwannoma of the oral cavity: review of the literature and report of a case. J Oral Med 1984; 39: 41-43
• 9 Stark A, Hugo HH, Buhl R et al. Tumoren peripherer Nerven. Dtsch Arztebl 2002; 99: A 928-933
• 10 Buric N, Jovanovic G, Pesic Z et al. Mandible schwannoma (neurilemmoma) presenting as periapical lesion. Dentomaxillofac Radiol 2009; 38: 178-181
• 11 Jahanshahi G, Haghighat A, Azmoodeh F. Intraosseous neurilemmoma of the mandible: report of a rare “ancient” type. Dent Res J (Isfahan) 2011; 8: 150-153
• 12 Chen CY, Wang WC, Chen CH et al. “ancient” schwannoma of the mouth floor – A case report and review. Oral Oncology Extra 2006; 42: 281-285
• 13 Handschel J, Heikaus S, Depprich R et al. Intraoral schwannoma: review of the literature and presentation of a rare case. Cranio 2012; 30: 150-153
• 14 Wright BA, Jackson D. Neural tumors of the oral cavity: a review of the spectrum of benign and malignant oral tumors of the oral cavity and jaws. Oral Surg Oral Med Oral Pathol 1980; 49: 509-522
• 15 Martins MD, Anunciato de Jesus L, Fernandes KP et al. Intra-oral schwannoma: case report and literature review. Indian J Dent Res 2009; 20: 121-125
• 16 Pfeifle R, Baur DA, Paulino A et al. Schwannoma of the tongue: report of 2 cases. J Oral Maxillofac Surg 2001; 59: 802-804
• 17 Klöppel G, Rudolph P, Cardesa A et al. Pathologie. Bd. 1, 3. Auflage, Berlin: Springer; 2009
• 18 Chan PT, Tripathi S, Low SE et al. Case report: “ancient” schwannoma of the scrotum. BMC Urology 2007; 7: 1
• 19 Humber CC, Copete MA, Hohn FI. “ancient” schwannoma of upper lip: case report with distinct histologic features and review of the literature. J Oral Maxillofac Surg 2011; 69: e118-e122
• 20 Zachariades N, Skoura C, Papageorgiou G et al. Giant “ancient” neurilemmoma of the cervical region: report of case. J Oral Maxillofac Surg 2001; 59: 668-672
• 21 Subhashraj K, Balanand S, Pajaniammalle S. “Ancient” schwannoma arising from mental nerve. A case report and review. Med Oral Patol Oral Cir Bucal 2009; 14: e12-e14
• 22 López-Carriches C, Baca-Pérez-Bryan R, Montalvo-Montero S. Schwannoma located in the palate: clinical case and literature review. Med Oral Patol Oral Cir Bucal 2009; 14: e465-e468
• 23 Cohen M, Wang MB. Schwannoma of the tongue: two case reports and review of the literature. Eur Arch Otorhinolaryngol 2009; 266: 1823-1929
• 24 Gainza-Cirauqui ML, Eguía-Del Valle A et al. “ancient” Schwannoma of the hard palate. An uncommon case report and review. J Clin Exp Dent 2013; 5: e62-e65
• 25 Sherman L, Xu HM, Geist RT et al. Interdomain binding mediates tumor growth suppression by the NF2 gene product. Oncogene 1997; 15: 2505-2509
• 26 Tikoo A, Varga M, Ramesh V et al. An anti-Ras function of neurofibromatosis type 2 gene product (NF2/Merlin). J Biol Chem 1994; 269: 23387-23390
• 27 McClatchey AI, Saotome I, Mercer K et al. Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors. Genes Dev 1998; 12: 1121-1133
• 28 Giovannini M, Robanus-Maandag E, Niwa-Kawakita M et al. Schwann cell hyperplasia and tumors in transgenic mice expressing a naturally occurring mutant NF2 protein. Genes Dev 1999; 13: 978-986
• 29 McClatchey AI, Saotome I, Mercer K et al. Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors. Genes Dev 1998; 12: 1121-1133
• 30 Giovannini M, Robanus-Maandag E, van der Valk M et al. Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes Dev 2000; 14: 1617-1630
• 31 Kalamarides M, Niwa-Kawakita M, Leblois H et al. Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. Genes Dev 2002; 16: 1060-1065
• 32 Trofatter JA, MacCollin MM, Rutter JL et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 1993; 72: 791-800
• 33 Rouleau GA, Merel P, Lutchman M et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 1993; 363: 515-521
• 34 Turunen O, Wahlstrom T, Vaheri A. Ezrin has a COOH-terminal actin-binding site that is conserved in the ezrin protein family. J Cell Biol 1994; 126: 1445-1453
• 35 McClatchey AI, Saotome I, Mercer K et al. Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors. Genes Dev 1998; 12: 1121-1133
• 36 Okada T, You L, Giancotti FG. Shedding light on Merlin’s wizardry. Trends Cell Biol 2007; 17: 222-229
• 37 Kaempchen K, Mielke K, Utermark T et al. Upregulation of the Rac1/JNK signaling pathway in primary human schwannoma cells. Human Molecular Genetics 2003; 12: 1211-1221
• 38 Gutmann DH. Molecular insights into neurofibromatosis 2. Neurobiol Dis 1997; 3: 247-261
• 39 Zang KD. Meningioma: a cytogenetic model of a complex benign human tumor, including data on 394 karyotyped cases. Cytogenet Cell Genet 2001; 93: 207-220
• 40 Evans JJ, Jeun SS, Lee JH et al. Molecular alterations in the neurofibromatosis type2 gene and its protein rarely occurring in meningothelial meningiomas. J Neurosurg 2001; 94: 111-117
• 41 Harada T, Irving RM, Xuereb JH et al. Molecular genetic investigation of the neurofibromatosis type 2 tumor suppressor gene in sporadic meningioma. J Neurosurg 1996; 84: 847-851
• 42 Trofatter JA, MacCollin MM, Rutter JL et al. A novel moesin-, ezrin-, radixin like gene is a candidate for theneurofibromatosis 2 tumor suppressor. Cell 1993; 75: 826
• 43 Rouleau GA, Merel P, Lutchman M et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 1993; 363: 515-521
• 44 Merel P, Haong-Xuan K, Sanson M et al. Predominant occurrence of somatic mutations of the NF2 gene in meningiomas and schwannomas. Genes Chromosomes 1995; 13: 211-216
• 45 Jacoby LB, MacCollin M, Barone R et al. Frequency and distribution of NF2 mutations in schwannomas. Genes Chromosomes 1996; 17: 45-55
• 46 Ruttledge MH, Andermann AA, Phelan CM et al. Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease. Am J Hum Genet 1996; 59: 331-342
• 47 Morrison H, Sherman LS, Legg J et al. The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev 2001; 15: 968-980
• 48 Shaw RJ, Paez JG, Curto M et al. The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling. Dev Cell 2001; 1: 63-72
• 49 Sherman LS, Gutmann DH. Merlin: hanging tumor suppression on the Rac. Trends Cell Biol 2001; 11: 442-444
• 50 Xiao GH, Beeser A, Chernoff J et al. p21-activated Kinase Links Rac/Cdc42 Signaling to Merlin. J Biol Chem 2002; 277: 883-886
• 51 Kissil JL, Johnson KC, Eckman MS et al. Merlin phosphorylation by p21-activated kinase 2 and effects of phosphorylation on merlin localization. J Biol Chem 2002; 277: 10394-10399
• 52 Rosenbaum C, Kluwe L, Mautner VF et al. Isolation and characterization of Schwann cells from neurofibromatosis type 2 patients. Neurobiol Dis 1998; 5: 55-64
• 53 Pelton PD, Sherman LS, Rizvi TA et al. Ruffling membrane, stress fiber, cellspreading and proliferation abnormalities in human Schwannoma cells. Oncogene 1998; 17: 2195-2209
• 54 Jacob A, Lee TX, Neff BA et al. Phosphatidylinositol 3-kinase/AKT pathway activation in human vestibular schwannoma. Otol Neurotol 2008; 29: 58-68
• 55 Flaiz C, Utermark T, Parkinson DB et al. Impaired intercellular adhesion and immature adherens junctions in merlin-deficient human primary schwannoma cells. Glia 2008; Apr; 56 (Suppl. 05) 506-515